<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/22/3278646/0/en/Press-Release-Sanofi-provides-update-on-the-regulatory-submission-for-Sarclisa-subcutaneous-in-the-US.html">Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target action date for its review of the biologics license application for Sarclisa (isatuximab-irfc) subcutaneous (SC) in combination with approved standard-of-care regimens for the treatment of patients ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/13/3272182/0/en/Press-Release-Sanofi-and-Regeneron-s-Dupixent-approved-in-the-EU-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria.html">Press Release: Sanofi and Regeneron&#39;s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi and Regeneron&#39;s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/07/3268809/0/en/Press-Release-Sanofi-s-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respiratory-studies-in-asthma-and-CRSwNP.html">Press Release: Sanofi&#39;s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi&#39;s lunsekimig met primary  and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP  The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status   The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig&#39;s potent...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/31/3265145/0/en/Press-Release-Sanofi-s-Rezurock-approved-in-the-EU-to-treat-chronic-graft-vs-host-disease.html">Press Release: Sanofi&#39;s Rezurock approved in the EU to treat chronic graft-vs-host disease</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi&#39;s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chron...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/28/3264184/0/en/Press-Release-AAD-new-results-from-Sanofi-s-amlitelimab-phase-3-studies-in-atopic-dermatitis-presented-in-late-breaking-research-session.html">Press Release: AAD: new results from Sanofi&#39;s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session</a>
    </div>

      <div class="me-0 me-md-5">
        AAD: new results from Sanofi&#39;s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-backs-sanofis-injectable-version-blood-cancer-drug-2026-03-27/">EU regulator backs Sanofi&#39;s injectable version of blood cancer drug</a>
    </div>

      <div class="me-0 me-md-5">
        French drugmaker Sanofi said on Friday the European Medicines Agency has recommended the ​approval of a subcutaneous version of ‌its blood cancer drug administered through an on-body injector.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/24/3260956/0/en/Press-release-Availability-of-the-Q1-2026-aide-m%C3%A9moire.html">Press release: Availability of the Q1 2026 aide-mémoire</a>
    </div>

      <div class="me-0 me-md-5">
        Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the &quot;Investors&quot; page of the company&#39;s website: First quarter 2026 results (sanofi.com) Prepared each quarter, this document is intented to support financial modelling of the quarterly results.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/24/3260948/0/en/Press-Release-Sanofi-and-Regeneron-s-Dupixent-approved-in-Japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid.html">Press Release: Sanofi and Regeneron&#39;s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi and Regeneron&#39;s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Sanofi-Sponsored-ADR-US80105N1054/load_more?page=8">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>